文献速递淋巴瘤

极早期FDG-PET指导的靶向治疗在初治晚期经典型霍奇金淋巴瘤中的II期试验

Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2026-01-01

EORTC-1537-COBRA单臂多中心II期试验纳入150例初治晚期经典型霍奇金淋巴瘤成人患者,接受1周期A-AVD后行FDG-PET指导治疗调整。PET阴性者继续A-AVD,阳性者换用BrECADD。

要点

  • 1周期A-AVD后PET指导可识别需强化治疗的高危患者。
  • 最常见3-4级不良事件为中性粒细胞减少(35%),无治疗相关死亡。

核心结论

  • 极早期PET指导的BrECADD强化治疗在晚期经典型霍奇金淋巴瘤中显示高活性,同时使多数患者免于强化化疗。

研究设计与样本

  • 单臂、多中心、II期试验,在7个国家16个中心开展。
  • 纳入150例18-60岁初治晚期经典型霍奇金淋巴瘤患者,WHO体能状态0-2,器官功能充足。
  • 所有患者接受1周期A-AVD后行中心审查的FDG-PET-CT(PET1)。
  • PET1阴性(Deauville评分1-3)接受额外5周期A-AVD;PET1阳性(Deauville评分4-5)换用6周期BrECADD。
  • 主要终点为2年改良无进展生存率(mPFS),可评估人群为145例。

主要发现

  • 150例患者中,PET1阴性90例(60%),阳性60例(40%)。
  • 最常见3-4级不良事件为中性粒细胞减少53例(35%),贫血18例(12%),外周感觉神经病变9例(6%)。
  • 严重不良事件发生于45例(30%),无死亡发生。

关键数值与推荐

  • PET1阴性定义为Deauville评分1-3,阳性定义为Deauville评分4-5。

临床怎么用

  • 对于初治晚期经典型霍奇金淋巴瘤,可在1周期A-AVD后行FDG-PET指导治疗调整。
  • PET1阳性患者换用BrECADD强化方案可能改善预后。
  • PET1阴性患者继续A-AVD,避免过度强化化疗。

局限性

  • 单臂设计,无随机对照,结论需进一步验证。
  • 样本量有限,随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine (A-AVD) improves outcomes in advanced-stage classic Hodgkin lymphoma, but patients with a positive early interim PET have inferior prognosis. We evaluated whether very early [18F]fluorodeoxyglucose ([18F]FDG)-PET-guided treatment adaptation after one cycle of A-AVD improves activity while limiting exposure to intensive chemotherapy. METHODS: This single-arm, multicentre, phase 2 trial was conducted at 16 centres in seven countries (the Netherlands, Spain, Denmark, Belgium, Portugal, Slovakia, and Poland). Adults aged 18-60 years with previously untreated advanced-stage classic Hodgkin lymphoma, WHO performance status 0-2, and adequate organ function received one cycle of A-AVD (brentuximab vedotin 1·2 mg/kg intravenously, doxorubicin 25 mg/m2 intravenously, vinblastine 6 mg/m2 intravenously, and dacarbazine 375 mg/m2 intravenously, all on days 1 and 15), followed by centrally reviewed [18F]FDG-PET-CT (PET1). PET1-negative (Deauville score 1-3) patients received five additional A-AVD cycles; PET1-positive (Deauville score 4-5) patients switched to six cycles of BrECADD (brentuximab vedotin 1·8 mg/kg intravenously on day 1; etoposide 150 mg/m2 intravenously on days 2-4; cyclophosphamide 1250 mg/m2 intravenously on day 2; doxorubicin 40 mg/m2 intravenously on day 2; dexamethasone 40 mg orally on days 2-5; dacarbazine 250 mg/m2 intravenously on days 3-4). The primary endpoint was 2-year modified progression-free survival (mPFS), defined as the proportion of patients alive and free of progression, relapse, or death from treatment start, with initiation of new systemic therapy for persistent disease counted as an event. Analyses were prespecified and conducted in the evaluable population (registered and eligible patients, who commenced the allocated treatment according to PET1 results after 1 cycle of A-AVD). The safety population consists of all patients who started A-AVD treatment (ie, received at least one dose of study therapy). This is the primary analysis of a completed trial. This trial is registered on ClinicalTrials.gov (NCT03517137) and EudraCT 2017-000498-35). FINDINGS: From Aug 1, 2019, to Aug 31, 2021, we enrolled 150 patients (81 males [54%] and 69 females [46%]; median age 32 years [IQR 23-39]) who received one cycle of A-AVD, after which 90 (60%) of them had a negative PET1 and 60 (40%) a positive result. 145 were evaluable for efficacy; the median follow-up at the clinical cutoff (Sept 1, 2023; database lock Dec 11, 2023) was 30·1 months (IQR 24·6-36·4). 16 patients experienced an mPFS event. The estimated 2-year mPFS was 89·5% (80% CI 85·7-92·4). The most common grade 3-4 adverse event was neutropenia (53 [35%] of 150) followed by anaemia (18 [12%]) and peripheral sensory neuropathy (nine [6%]). Serious adverse events occurred in 45 (30%) of 150 patients. No deaths occurred. INTERPRETATION: Very early PET-guided intensification with BrECADD yields high activity in advanced-stage classic Hodgkin lymphoma while sparing most patients intensive chemotherapy. FUNDING: Takeda Oncology.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Hutchings M, Diepstra A, Sureda Balari A, et al. Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2026. PMID: 42069408. doi:10.1016/S2352-3026(26)00068-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。